PGP9.5 as a prognostic factor in pancreatic cancer.
The expression of PGP9.5 was evaluated using immunohistochemistry in 69 resected ductal carcinomas of the pancreas and in normal pancreatic tissue. Overexpression did not seem to differ with histological type or pathological stage. A significant negative correlation was found between overexpression of PGP9.5 and postoperative survival. Multivariate analysis also suggested PGP9.5 along with tumor stage and extrapancreatic plexus invasion as strong predictors of the outcome. This study suggests that PGP9.5 expression may be used as a marker for predicting the outcome of resection-treated pancreatic cancer patients.
Tezel
E
E
Department of Surgery II, Nagoya University School of Medicine, Japan.
Hibi
K
K
Nagasaka
T
T
Nakao
A
A
D000230:Adenocarcinoma / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000943:Antigens, Differentiation / Q000096:biosynthesis*; D002277:Carcinoma / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors; D043222:Ubiquitin Thiolesterase
D000943:Antigens, Differentiation; D043222:Ubiquitin Thiolesterase